PharmaResearch Co Ltd
KOSDAQ:214450
PharmaResearch Co Ltd
Intangible Assets
PharmaResearch Co Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Intangible Assets
₩19.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Intangible Assets
₩1.8T
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Intangible Assets
₩67.1B
|
CAGR 3-Years
58%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Intangible Assets
₩109.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Intangible Assets
₩1.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Intangible Assets
₩112B
|
CAGR 3-Years
115%
|
CAGR 5-Years
182%
|
CAGR 10-Years
102%
|
|
PharmaResearch Co Ltd
Glance View
In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.
See Also
What is PharmaResearch Co Ltd's Intangible Assets?
Intangible Assets
19.5B
KRW
Based on the financial report for Dec 31, 2024, PharmaResearch Co Ltd's Intangible Assets amounts to 19.5B KRW.
What is PharmaResearch Co Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-8%
Over the last year, the Intangible Assets growth was -4%. The average annual Intangible Assets growth rates for PharmaResearch Co Ltd have been -9% over the past three years , -8% over the past five years .
You don't have any saved screeners yet